从优先治疗到全民治疗:意大利丙型肝炎病毒消除的成功与挑战
意大利曾是欧洲丙型肝炎病毒(HCV)感染和HCV相关肝癌死亡率最高的国家。直接抗病毒药物(DAA)最初仅限晚期纤维化患者,现已扩展至所有感染者,迄今已治疗超过244 000人。预计到2030年HCV肝相关死亡率下降75%,达到世界卫生组织死亡率目标,但意大利可能无法实现2030年消除HCV感染的总体目标。
要点
- 意大利HCV感染和HCV相关肝癌死亡率曾居欧洲首位。
- DAA治疗已从晚期纤维化扩展至所有感染者,累计治疗超过244 000人。
- 预计2030年HCV肝相关死亡率下降75%,但消除HCV感染的总体目标可能无法实现。
核心结论
- 意大利预计到2030年HCV肝相关死亡率下降75%,达到世界卫生组织死亡率目标,但可能无法实现2030年消除HCV感染的总体目标。
研究设计与样本
- 本文为综述,概述意大利HCV消除的挑战与建议。
主要发现
- 意大利曾是欧洲HCV感染和HCV相关肝癌死亡率最高的国家。
- DAA最初限于晚期纤维化患者,现已扩展至所有感染者,迄今治疗超过244 000人。
临床怎么用
- 作者建议扩大其他人群的筛查项目、通过战略沟通提高认识、维持DAA可及性,并定制护理模式以满足关键人群需求。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with advanced fibrosis, their use has since been extended to all infected individuals; more than 244 000 persons have been treated to date. HCV liver-related mortality is expected to decline by 75% by 2030, achieving the World Health Organization target for mortality. However, Italy risks failing to meet the overall goal of eliminating HCV infection by 2030. In this light, €71.5 million have been allocated for screening initially specific target populations (persons who inject drugs, prison inmates, and the 1969-1989 birth cohort). Herein, we outline the challenges and recommendations for how to move Italy toward HCV elimination, including expanding screening programs in other populations, increasing awareness through strategic communication, sustaining DAA access, and tailoring care models to meet the needs of key populations.
引用
- Kondili LA, Craxì L, Nava F, et al. From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy. J Infect Dis. 2023. PMID: 37703346. doi:10.1093/infdis/jiad038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。